„Mental clarity,” „concentration support,” and „NAD+ brain restoration therapy” are common terms used in cognitive marketing. These claims should be separated from research on specific diseases, such as Alzheimer's and Parkinson's disease, which we discuss in our disease research guide. This article focuses on what is currently known about NAD+ in the brain more broadly, including its role in neuronal energy metabolism, the scientific basis for concentration and mental clarity claims, whether „NAD+ brain restoration therapy” is a recognized treatment, and what research shows regarding sleep, anxiety, and mood.
The role of NAD+ in neuronal energy metabolism
The brain is one of the organs with the highest metabolic demands in the human body. Although it constitutes only a small fraction of total body weight, at rest it consumes a disproportionately large share of the body's energy. Neurons are heavily dependent on the efficient functioning of mitochondria to meet this constant energy demand [1].
The fundamental role of NAD+ in energy metabolism is also directly related to brain tissue. NAD+ participates in electron transfer reactions associated with the production of ATP, which neurons constantly need for basic processes such as maintaining the electrical membrane potential, producing neurotransmitters, ion transport, and supporting synaptic signaling [1,2].
Beyond energy metabolism, NAD+ also participates in several other cellular processes essential for the brain. It acts as a substrate for sirtuins and PARP enzymes, which are active in neurons and participate, among other things, in gene regulation, cellular stress response, and DNA repair [2].
NAD+ levels in the human brain can currently be measured non-invasively using specialized magnetic resonance spectroscopy (MRS) techniques. Studies using these methods have shown that NAD+ levels in the brain appear to decrease with age, similarly to what is observed in several other tissues [3]. This measurable decline is one of the findings that has contributed to scientific interest in NAD+ metabolism and brain aging.
What are the marketing claims of „mental clarity” and „concentration” based on?
Claims regarding „mental clarity” and „focus” are often linked to NAD+ products, but the scientific evidence behind these specific terms is much less direct than their wording might suggest.
General reasoning usually starts with neuronal energy metabolism. Neurons require a large and constant amount of energy, and NAD+ is essential for the metabolic pathways involved in ATP production. Based on this, it is sometimes assumed that increasing the availability of NAD+ will improve brain energy metabolism and, consequently, also cognitive functions such as concentration, focus, or mental clarity.
Such reasoning is biologically plausible because the individual stages involve well-established biological processes. However, the combination of these mechanisms alone does not prove that NAD+ precursor supplementation improves subjective focus or mental clarity in humans.
No published, placebo-controlled, randomized human trials have been identified that use validated, standardized measurements of „concentration” or „mental clarity” as primary endpoints for NAD+ precursor supplementation in healthy adults.
The closest evidence comes from studies in specific clinical populations, including individuals with mild cognitive impairment or Parkinson's disease. These studies typically used objective cognitive tests, imaging, biomarkers, or disease-specific parameters rather than subjective assessments of mental clarity.
Importantly, some studies have shown that NAD+ precursors can increase brain NAD+ levels without a concurrent significant improvement in all evaluated cognitive functions. This distinction clearly illustrates the difference between changing a biomarker and demonstrating a meaningful cognitive benefit.
For this reason, claims that NAD+ products reliably improve concentration or mental clarity should not be treated as established clinical effects unless supported by controlled human studies using appropriate cognitive endpoints.
What is „NAD+ brain restoration therapy,” and is it a recognized treatment method?
„NAD+ brain restoration therapy” is not a recognized category of medical treatment defined in peer-reviewed clinical literature or by major regulatory agencies. It is primarily a commercial or marketing term.
This term is typically used to describe the intravenous or injectable administration of NAD+ promoted for cognitive or neurological purposes, including claims such as improving brain fog, slowing cognitive decline, supporting addiction recovery, or general „neurological restoration.”.
There are actual human studies testing whether increasing NAD+ affects the brain in a measurable way, but the scope of this evidence is much narrower than the broad term „brain restoration” suggests.
One important example is the NADPARK phase I trial. In this study, oral nicotinamide riboside was administered to individuals with Parkinson's disease. The researchers found that NR increased brain NAD+ levels and was associated with changes in several biological biomarkers as well as minor clinical changes [4].
This study utilized controlled clinical methods and direct measurements of brain NAD+ metabolism. However, it was conducted in a specific patient population and used oral nicotinamide riboside rather than intravenously or injectably administered NAD+.
In a separate Phase I pharmacokinetic study, changes in blood and brain NAD+ levels were evaluated during repeated oral administration of the precursor. Blood NAD+ levels increased earlier, whereas measurable changes in brain NAD+ developed more slowly and became detectable after about four weeks of regular use [5].
These results provide evidence that oral NAD+ precursors can alter measurable brain NAD+ levels over time.
However, they do not confirm „NAD+ brain restoration therapy” as a general treatment for brain fog, cognitive decline, concentration problems, or neurological recovery. Nor do they prove that intravenous or injectable NAD+ produces equivalent effects in the brain.
Controlled evidence from human studies regarding increasing NAD+ levels in the brain largely comes from precisely defined research conditions, specific populations, oral administration of precursors, and objective imaging or biomarker assay methods. This differs significantly from the broad claims often associated with commercial „brain restoration” programs.
Does NAD+ affect sleep, anxiety, or mood?
Sleep was evaluated in at least one significant controlled human study.
In a randomized, placebo-controlled, double-blind study, 250 mg of NMN per day was administered for 12 weeks to older adults. Physical performance, blood NAD+-related metabolites, and several additional sleep- and stress-related outcomes were evaluated [6].
The primary endpoint, involving the step test, showed no significant difference between the groups. However, participants receiving NMN maintained their walking speed, while a decrease was observed in the placebo group, and an improvement in sleep quality was also noted in the NMN group as a secondary outcome [6].
This constitutes controlled human trial evidence relevant to sleep, but the interpretation should remain cautious. Sleep quality was a secondary endpoint rather than a primary one, meaning the study was not designed or adequately powered primarily to establish the efficacy of NMN for sleep problems.
This result would therefore need to be replicated in studies designed specifically to assess sleep, using validated sleep measures as pre-specified primary endpoints.
Evidence regarding anxiety and mood is more indirect.
Studies analyzing genetic data from the Taiwan Biobank have identified associations between variants in genes involved in NAD+-related metabolic pathways—including the kynurenine pathway and nicotinate metabolism—and the risk of major depressive disorder [7].
This suggests that NAD+-related metabolism may be linked to susceptibility to depression or related biological pathways in some individuals.
However, these were genetic association studies. They do not prove that increasing NAD+ through supplementation improves symptoms of depression, anxiety, or mood disorders.
No published randomized, placebo-controlled human study evaluating the NAD+ precursor specifically as a treatment for anxiety or depression has been identified.
Therefore, the evidence linking NAD+ to mood disorders remains largely mechanistic, genetic, or associative rather than interventional.
What has actually been studied and what remains anecdotal?
Current evidence can be divided into several levels of confirmation.
Controlled human studies have directly analyzed age-related changes in brain NAD+ levels using specialized MRS imaging [3].
Human pharmacokinetic studies have also shown that oral NAD+ precursors can increase NAD+ levels in the blood, and more slowly in the brain as well [5].
The Phase I NADPARK trial demonstrated an increase in brain NAD+ levels in Parkinson's disease patients, along with associated biomarker changes and minor clinical changes [4].
A 12-week NMN study in older adults also showed improvements in sleep quality as a secondary outcome [6].
At another level of evidence, genetic studies have shown links between NAD+-related metabolic pathways and the risk of major depressive disorder [7]. These results are useful for understanding possible biological relationships, but they do not confirm therapeutic effects.
In turn, several popular claims directed at consumers have not been directly confirmed in controlled human studies.
This concerns the reliable improvement of „concentration,” „mental clarity,” or similar subjective cognitive functions in healthy adults.
This also applies to the use of NAD+ precursors as a proven treatment for anxiety or depression.
„NAD+ brain restoration therapy” also remains a marketing term rather than a validated clinical treatment category.
The overall picture of the evidence is therefore inconclusive. There is significant human research on brain NAD+ metabolism, particularly regarding cerebral pharmacokinetics, age-related changes, and selected disease contexts. However, many frequently repeated claims regarding general enhancement of cognitive abilities, concentration, mental clarity, or broadly understood neurological recovery remain significantly less directly supported.
Realistic expectations regarding cognitive effects
The role of NAD+ in neuronal energy metabolism is well documented. Neurons require NAD+-dependent metabolic pathways for ATP production, and NAD+ is also involved in cellular functions encompassing sirtuins, PARPs, the stress response, and DNA repair [1,2].
Controlled studies in humans have also shown that oral NAD+ precursors can increase NAD+ levels in the blood and, more gradually, in the brain as well [5].
Under specific conditions, additional outcomes were also noted. These include an increase in brain NAD+ and associated biomarker changes or minor clinical changes in Parkinson's disease studies [4], as well as an improvement in sleep quality as a secondary outcome in one NMN study in older adults [6].
These results are scientifically significant, but have a much narrower scope than general claims about improving cognitive function.
Current research does not show that NAD+ precursor supplementation reliably improves concentration, mental clarity, focus, memory, or overall cognitive performance in healthy adults.
They also do not support „NAD+ brain restoration therapy” as a validated treatment category for cognitive decline, brain fog, mood disorders, or neurological recovery.
It is especially important to distinguish between measurable changes in brain NAD+ levels and a clinically significant improvement in cognitive function. An increase in the biomarker does not automatically mean an improvement in cognitive function.
Similarly, the results obtained in specific populations with diseases should not be automatically extrapolated to healthy adults seeking to improve cognitive performance.
Individuals considering NAD+ supplementation due to persistent cognitive issues, sleep disturbances, anxiety, or mood changes should also keep in mind that these symptoms can have many possible causes. An evidence-based medical or psychological evaluation may be more appropriate than assuming the symptoms stem from NAD+ levels.
Limitations of current evidence
- No published controlled human trials utilizing validated measures of „concentration” or „mental clarity” as primary endpoints for NAD+ precursor supplementation in healthy adults have been identified.
- The strongest evidence regarding the human brain, including pharmacokinetic data on NAD+ in the brain and biomarker studies in Parkinson's disease, comes from relatively small studies and strictly defined clinical populations. These results cannot be automatically extrapolated to healthy adults seeking a general cognitive enhancement [4,5].
- Proof that oral NAD+ precursors can increase brain NAD+ levels does not mean that such an increase improves memory, attention, concentration, executive function, or subjective mental clarity.
- The discussed improvement in sleep quality was a secondary rather than a primary endpoint. Therefore, it requires confirmation in studies specifically designed and adequately powered to assess sleep parameters [6].
- Evidence linking NAD+-related metabolism to depression is primarily genetic and associative rather than interventional. Such findings do not prove that NAD+ supplementation treats depression or anxiety [7].
- No randomized, placebo-controlled human study confirming the NAD+ precursor as a treatment for anxiety or depressive disorders has been identified.
- The results of research on Parkinson's disease should not be generalized to other neurological diseases, healthy aging, or general cognitive improvement without appropriate studies in these populations [4].
- „NAD+ brain restoration therapy” is not a defined or recognized treatment category in peer-reviewed medical literature, and this term should not be interpreted as evidence of the existence of a validated neurological therapy under such a name.
- Controlled evidence showing that oral NAD+ precursors affect brain NAD+ levels does not automatically support equivalent claims for intravenous, intramuscular, subcutaneous, sublingual, or other routes.
- Changes in NAD+ biomarkers, imaging measurements, inflammatory markers, or other biological signals do not in themselves prove a clinically significant improvement in cognitive function, mood, sleep, or neurological health.
- Subjective reports regarding improvements in concentration, mental clarity, or mood can be influenced by the placebo effect, sleep, stress, caffeine intake, medications, physical activity, diet, underlying medical conditions, and other factors that are difficult to control outside of clinical trials.
Disclaimer
The article is for educational purposes only and summarizes scientific research. It does not constitute medical, neurological, psychiatric, or psychological advice.
NAD+ and its precursors should not be presented as FDA- or EMA-approved treatments for cognitive impairment, brain fog, anxiety, depression, sleep disorders, Parkinson's disease, Alzheimer's disease, or other neurological or psychiatric conditions, unless referring to a specific approved medicinal product and indication.
The evidence summarized here includes basic neurobiology, biomarker studies, pharmacokinetic studies, genetic association studies, and early human clinical trials. Changes in brain NAD+ levels, biomarkers, or other biological measurements should not be interpreted as evidence of improved cognitive function or treatment efficacy.
Persistent problems with memory, concentration, sleep, anxiety, mood, or other cognitive symptoms can have many possible causes, including neurological, psychiatric, endocrinological, cardiovascular, metabolic, medication-related, nutritional, or sleep-related ones.
Individuals experiencing persistent or worsening cognitive problems, sleep disturbances, anxiety, or mood disorders should seek an evaluation from a suitably qualified healthcare professional or mental health specialist rather than relying solely on NAD+ supplementation. Before starting any new supplement or therapy, you should consult a qualified healthcare professional, particularly during pregnancy or breastfeeding, when treating a chronic somatic or psychiatric condition, or while taking prescription medications concurrently.
References
[1] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[2] Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x
[3] Bagga, P., Hariharan, H., Wilson, N. E., Beer, J. C., Shinohara, R. T., Elliott, M. A., Baur, J. A., Marincola, F. M., Witschey, W. R., Haris, M., Detre, J. A., & Reddy, R. (2020). Single-voxel ¹H MR spectroscopy of cerebral nicotinamide adenine dinucleotide (NAD+) in humans at 7T using a 32-channel volume coil. Magnetic Resonance in Medicine, 83(3), 806–814. https://doi.org/10.1002/mrm.27971
[4] Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Craven, A. R., Schwarzlmüller, T., Brekke, N., Diab, J., Sverkeli, L., Skjeie, V., Varhaug, K., Tysnes, O.-B., Peng, S., Haugarvoll, K., Ziegler, M., Grüner, R., Eidelberg, D., & Tzoulis, C. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metabolism, 34(3), 396–407.e6. https://doi.org/10.1016/j.cmet.2022.02.001
[5] Berven, H., Svensen, M., Eikeland, H., Tvedten, N., Sheard, E. V., Amdahl Af Geijerstam, S., Søgnen, M., McCann, A., Arnsten, L., Årseth, O., Skjeie, V., Hjellbrekke, A., Skeie, G.-O., Torres Cleuren, Y. N., Nido, G. S., Haugarvoll, K., Riemer, F., Tzoulis, C., & Dölle, C. (2026). The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience, 29(3), 114764. https://doi.org/10.1016/j.isci.2026.114764
[6] Morifuji, M., Higashi, S., Ebihara, S., & Nagata, M. (2024). Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience, 46(5), 4671–4688. https://doi.org/10.1007/s11357-024-01204-1
[7] Chen, D. T.-L., Cheng, S.-W., Chen, T., Chang, J. P.-C., Hwang, B.-F., Chang, H.-H., Chuang, E. Y., Chen, C.-H., & Su, K.-P. (2022). Identification of genetic variations in the NAD-related pathways for patients with major depressive disorder: A case-control study in Taiwan. Journal of Clinical Medicine, 11(13), 3622. https://doi.org/10.3390/jcm11133622